Chronic Lymphocytic Leukemia

The final analysis of the phase 1/2 BRUIN trial showed consistent stability or improvements in PROs with pirtobrutinib in CLL/SLL and MCL.

Jennifer R. Brown, MD, PhD, discusses the design of the AMPLIFY trial and safety data for acalabrutinib plus venetoclax in chronic lymphocytic leukemia.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, head and neck cancer, breast cancer, prostate cancer, and leukemia.

Jennifer R. Brown, MD, PhD, discusses the FDA approval of acalabrutinib plus venetoclax for chronic lymphocytic leukemia and how it improves QOL.

Jennifer R. Brown, MD, PhD, discusses ongoing clinical trials that she has her eye out for in chronic lymphocytic leukemia.

Jennifer R. Brown, MD, PhD, discusses the FDA approval of acalabrutinb and venetoclax for chronic lymphocytic leukemia and its effect on patient QOL.

In a post hoc indirect comparison, data showed zanubrutinib was linked to improved PFS vs acalabrutinib/venetoclax in patients with treatment-naive CLL.

Mazyar Shadman, MD, MPH, discusses a post hoc analysis that compared data BTK inhibitor–based regimens for treatment-naive chronic lymphocytic leukemia.

The top 5 OncLive TV videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, lung cancer, breast cancer, and prostate cancer.

Nicole Lamanna, MD, discusses both CLL 17 and FLAIR studies and their significance for chronic lymphocytic leukemia.

Nicole Lamanna, MD, discusses the implications of the FDA approval of frontline acalabrutinib plus venetoclax in CLL.

Nicole Lamanna, MD, discusses the FDA approval of first-line acalabrutinib plus venetoclax for CLL and the phase 3 AMPLIFY trial data that supported it.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

Pirtobrutinib has been approved for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma in China.

Real-world data show liso-cel drives high responses in relapsed/refractory CLL, with an 85% ORR, a 44% CR rate, and manageable safety.

The FDA approved a frontline acalabrutinib regimen in CLL/SLL and a simplified dosing schedule for Rybrevant Faspro in EGFR+ NSCLC and will review NDAs in PCNSL and breast cancer.

The FDA has approved acalabrutinib plus venetoclax for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dual CD19- and CD20-targeting CAR T-cell therapy was effective and had a unique safety profile in patients with relapsed/refractory CLL.

Obinutuzumab in combination with venetoclax yielded responses in chronic lymphocytic leukemia and small lymphocytic leukemia.

An ML-NMR analysis associated zanubrutinib with PFS improvements vs ibrutinib or acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in January 2025 spanning tumor types.

Ahead of the 2026 Transplantation & Cellular Therapy Meetings, experts preview data on CAR T-cell therapy efficacy, donor access, and toxicity mitigation.

Andrew Lipsky, MD, discusses data with pirtobrutinib in relapsed/refractory CLL and the effect of its FDA approval on sequencing decisions for this disease.

Ianalumab plus ibrutinib showed promising efficacy and uMRD rates with manageable safety in a phase 1b study of patients with CLL.

Nemtabrutinib plus venetoclax showed early activity and manageable safety in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.